Enovis Corporation (ENOV)
NYSE:ENOV
Want to see ENOV full AI Analyst Report?
ENOV Stock Chart & Stats
$26.32
$0.83(1.85%)
At close: 4:00 PM EST
$26.32
$0.83(1.85%)
Day’s Range― - ―
52-Week Range$20.82 - $36.82
Previous CloseN/A
Volume391.51K
Average Volume (3M)1.11M
Market Cap
$1.36B
Enterprise Value$2.68B
Total Cash (Recent Filing)$33.13M
Total Debt (Recent Filing)$1.41B
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Jul 30, 2026EPS Estimate
0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.02
Shares Outstanding57,562,603
10 Day Avg. Volume1,057,080
30 Day Avg. Volume1,114,582
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.02
Price to Sales (P/S)0.67
P/FCF Ratio75.96
Enterprise Value/Market Cap1.97
Enterprise Value/Revenue1.18
Enterprise Value/Gross Profit2.07
Enterprise Value/Ebitda-13.92
Forecast
1Y Price Target
$42.33Price Target Upside60.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)3.65
Revenue Forecast (FY)$2.35B
Bulls Say, Bears Say
Bulls Say
High Gross MarginEnovis’s ~60% gross margin combined with sustained revenue expansion provides durable operating leverage. If the company continues to grow volumes and improve mix, gross margin strength supports scalable profit recovery, enabling incremental EBITDA and funding for reinvestment over the next 2–6 months.
Improving Cash GenerationManagement’s demonstrated FCF improvement (+$16M in Q1) and explicit >25% conversion target signal a structural shift toward cash-positive operations. Stronger FCF supports debt flexibility, organic investment and product rollout funding, reducing reliance on external financing over a multi-quarter horizon.
Innovation & Commercial MomentumNew product platforms (Arvis, Nebula) and a flexible commercial model for ASCs create durable competitive advantages. These innovations drive surgeon conversions, expand addressable markets (ASCs, extremities) and improve long‑term procedure mix and utilization trends beyond short-term cycles.
Bears Say
Severe Profitability WeaknessThe swing from near‑break‑even to very large operating and net losses is a persistent structural risk. Deep negative margins depress returns on capital, limit reinvestment capacity, and may force sustained cost actions or restructuring if revenue/mix improvements don’t translate to durable operating profits.
Tariff & Geopolitical ExposureRecurring tariff costs and concentrated international disruptions create a structural margin headwind and cash flow volatility. Ongoing geopolitical risk and trade frictions can persist for many quarters, pressuring gross margins and complicating long‑term planning for supply chain and pricing.
Cost Structure & Cash VolatilityRising R&D and capital investment to support Recon growth, combined with historical cash flow inconsistency, can sustain elevated spending without immediate profit offset. If top-line or margin gains lag, higher structural operating and investing costs will constrain durable margin recovery and free cash flow resilience.
Enovis News
ENOV FAQ
What was Enovis Corporation’s price range in the past 12 months?
Enovis Corporation lowest stock price was $20.82 and its highest was $36.82 in the past 12 months.
What is Enovis Corporation’s market cap?
Enovis Corporation’s market cap is $1.36B.
When is Enovis Corporation’s upcoming earnings report date?
Enovis Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 51 days.
How were Enovis Corporation’s earnings last quarter?
Enovis Corporation released its earnings results on May 07, 2026. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.812 by $0.078.
Is Enovis Corporation overvalued?
According to Wall Street analysts Enovis Corporation’s price is currently Undervalued.
Does Enovis Corporation pay dividends?
Enovis Corporation does not currently pay dividends.
What is Enovis Corporation’s EPS estimate?
Enovis Corporation’s EPS estimate is 0.85.
How many shares outstanding does Enovis Corporation have?
Enovis Corporation has 57,562,603 shares outstanding.
What happened to Enovis Corporation’s price movement after its last earnings report?
Enovis Corporation reported an EPS of $0.89 in its last earnings report, beating expectations of $0.812. Following the earnings report the stock price went up 9.658%.
Which hedge fund is a major shareholder of Enovis Corporation?
Currently, no hedge funds are holding shares in ENOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.33 (60.84% Upside)
$42.33 (60.84% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 563.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $142.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.9%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.51%
12-Months-Change
Fundamentals
Return on Equity
-60.13%
Trailing 12-Months
Asset Growth
-21.39%
Trailing 12-Months
Company Description
Enovis Corporation
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
ENOV Company Deck
ENOV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed solid operational execution and clear commercial momentum—particularly in Recon and extremities—with meaningful innovation catalysts (Arvis, Nebula), margin expansion at the gross level, EPS growth, and improved free cash flow. However, offsetting risks include tariff costs (~$4M), international volatility including Middle East exposure (~$1–2M/month), a Q1 selling-days headwind (~240 bps), a conservative stance on guidance, and an SEC-driven change to adjusted EBITDA presentation that reduces non-GAAP comparability. On balance, positive fundamental performance and a constructive outlook outweigh the near-term headwinds and reporting adjustments.View all ENOV earnings summariesENOV Stock 12 Month Forecast
Average Price Target
$42.33
▲(60.84% Upside)
Technical Analysis
Ownership Overview
2.08% Insiders
34.85% Mutual Funds
31.93% Other Institutional Investors
0.29% Public Companies and
Individual Investors